Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jaclyn Smith (Manchester, United Kingdom), Amelie Harle, Fiona Blackhall, Alex Molassiotis, Kim Holt, Rachel Dockry, Philip Russell, Katy Burns, Ryan Robinson, Mark Birrell, Maria Belvisi, Jaclyn Smith. Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer. Eur Respir J 2016; 48: Suppl. 60, 5060

Member's Comments

No comment yet.

Related content which might interest you: An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Cough receptor sensitivity to capsaicin in patients with lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 104s Year: 2001 Expression of CysLT2 receptors in asthmatic lung, and the roles in bronchoconstriction Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 H4 receptor antagonits as a potential medication for upper airway cough syndrom Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006 Low level laser in monotherapy or in combination with leukotriene receptor antagonists in the treatment of allergic lung inflammation Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013 Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013 Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Combined loss of M2 and M3 muscarinic acetylcholine receptor (mAChR) function in mutant mice increases serotonin airway responsiveness (AR) Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019